| scholarly article | Q13442814 |
| P2093 | author name string | Qing Li | |
| Peng Yuan | |||
| Yang Luo | |||
| Ying Fan | |||
| Binghe Xu | |||
| Jiayu Wang | |||
| Fei Ma | |||
| Pin Zhang | |||
| Qiao Li | |||
| Ruigang Cai | |||
| Jihong Guo | |||
| P2860 | cites work | Trastuzumab containing regimens for early breast cancer | Q24200192 |
| Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab | Q27640593 | ||
| Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer | Q27824847 | ||
| Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 | Q27860674 | ||
| Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene | Q27860693 | ||
| Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer | Q29616112 | ||
| Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis | Q30004190 | ||
| Poor outcome of hormone receptor-positive breast cancer at very young age is due to tamoxifen resistance: nationwide survival data in Korea--a report from the Korean Breast Cancer Society | Q31113303 | ||
| Trastuzumab in combination with weekly paclitaxel and carboplatin as neo-adjuvant treatment for HER2-positive breast cancer: The TRAIN-study. | Q33440357 | ||
| Paclitaxel, Carboplatin, and trastuzumab | Q34612916 | ||
| Adjuvant trastuzumab in HER2-positive breast cancer | Q35710898 | ||
| Prognostic and predictive factors in early-stage breast cancer | Q35961914 | ||
| Effect of adjuvant trastuzumab treatment in conventional clinical setting: an observational retrospective multicenter Italian study | Q37136423 | ||
| Outcomes of her2-positive early-stage breast cancer in the trastuzumab era: a population-based study of Canadian patients | Q37364604 | ||
| Guideline concordant therapy prolongs survival in HER2-positive breast cancer patients: results from a large population-based cohort of a cancer registry | Q37687943 | ||
| 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial | Q38953228 | ||
| Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease | Q40630247 | ||
| Young age as an adverse prognostic factor in premenopausal women with operable breast cancer | Q43803351 | ||
| Concurrent administration of trastuzumab and anthracyclines as adjuvant regimen for HER2-positive breast cancer: a randomised controlled trial | Q44885336 | ||
| Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial | Q46736552 | ||
| Cancer incidence and mortality in China, 2014. | Q52653171 | ||
| Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. | Q53158182 | ||
| 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. | Q53243856 | ||
| HER2 and responsiveness of breast cancer to adjuvant chemotherapy. | Q54600960 | ||
| Adjuvant Capecitabine, Docetaxel, Cyclophosphamide, and Epirubicin for Early Breast Cancer: Final Analysis of the Randomized FinXX Trial | Q57278896 | ||
| Chinese guidelines for diagnosis and treatment of breast cancer 2018 (English version). | Q64988020 | ||
| HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15 | Q73308218 | ||
| erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer | Q77331949 | ||
| erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer | Q77331953 | ||
| Management and outcome of HER2-positive early breast cancer treated with or without trastuzumab in the adjuvant trastuzumab era | Q84097268 | ||
| P433 | issue | 5 | |
| P921 | main subject | trastuzumab | Q412616 |
| Erb-b2 receptor tyrosine kinase 2 | Q415271 | ||
| P304 | page(s) | 759-770 | |
| P577 | publication date | 2019-10-01 | |
| P1433 | published in | Chinese Journal of Cancer Research | Q26841836 |
| P1476 | title | Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2 (HER2)-positive early-stage breast cancer: A real-world retrospective study in Chinese patients | |
| P478 | volume | 31 |
| Q97643993 | Effectiveness of second-line anti-HER2 treatment in HER2-positive metastatic breast cancer patients previously treated with trastuzumab: A real-world study | cites work | P2860 |
Search more.